Guselkumab demonstrated superior long-term responses compared with secukinumab in the treatment of moderate-to-severe plaque psoriasis in the first head-to-head trial (the ECLIPSE study) comparing an IL-23 inhibitor (guselkumab) to an IL-17 inhibitor (secukinumab); but there may be limitations to these data and more research is needed.
Prof. Kristian Reich (Georg-August-University Göttingen, Germany) reminded us that there are two main novel classes of drugs in psoriasis, the IL-17 and IL-23 inhibitors, and it will be interesting to discover what their similarities and differences might be in clinical outcomes . The role that the cytokines play in the pathological cascade of psoriasis is very different; for example, while anti-IL-23 drugs can allow you to go to longer injection intervals, you have a very rapid onset of response if you block IL-17. Wh...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis Next Article
Live imaging of cutaneous immune responses »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.